Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generics Body Attacks WHO's 'Immature' Biological Qualifier Scheme

This article was originally published in SRA

Executive Summary

The World Health Organization's 'biological qualifier' scheme has its supporters and its detractors, with the former believing it will improve drug use and monitoring, and the latter thinking it at best superfluous and at worst a potential source of confusion and regulatory misalignment.

You may also be interested in...



WHO To Pilot ‘Biological Qualifier’ Scheme Despite Protests From Biosimilars Industry

The World Health Organization has decided to pursue its “Biological Qualifier” scheme despite concerns that it may conflict with other traceability systems. Calls by the European biosimilars industry to put the scheme on ice appear to have fallen on deaf ears.

WHO To Pilot ‘Biological Qualifier’ Scheme Despite Protests From Biosimilars Industry

The World Health Organization has decided to pursue its “Biological Qualifier” scheme despite concerns that it may conflict with other traceability systems. Calls by the European biosimilars industry to put the scheme on ice appear to have fallen on deaf ears.

French Agency Sets Up New Body To Advise On Biosimilar Substitution

The new committee, which will initially be in place for a year, will advise the French drug regulator when it is preparing its opinions on substitution in specific biosimilar product groups.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS118564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel